SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265271.
  • 2
    Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995; 13: 14301435.
  • 3
    Schiller JH, Kim KM, Hutson P, et al. Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1996; 14: 23452352.
  • 4
    Latreille J, Cormier Y, Martins H, et al. Phase II trial of docetaxel (Taxotere) in patients with previously untreated small cell lung cancer. Invest New Drugs. 1996; 13: 343345.
  • 5
    Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994; 5: 283285.
  • 6
    Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992; 10: 12251229.
  • 7
    Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small- cell lung cancer. A Phase II study in patients with refractory and sensitive disease. J Clin Oncol. 1997; 15: 20902096.
  • 8
    Van Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658667.
  • 9
    Hainsworth JD, Gray JR, Stroup SL, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential Phase II trials using different dose-intensities. J Clin Oncol. 1997; 15: 34643470.
  • 10
    Jacobs SA, Jett JR, Belani CP, et al. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 470a.
  • 11
    Hainsworth JD, Burris HA, Hopkins LG, Greco FA. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (G-CSF) in the treatment of patients with advanced refractory cancer. Cancer. 1999; 85: 11791186.
  • 12
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 17481756.
  • 13
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 3138.
  • 14
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 15
    Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1994; 3: 14711477.
  • 16
    Boni C, Cocconi G, Bisagni G, et al. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer: a Phase II trial. Cancer. 1989; 63: 638642.
  • 17
    Kosmidis PA, Samantas E, Fountzilas G, et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized Phase III study. Semin Oncol. 1994; 21( Suppl 6): 2330.
  • 18
    Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10: 282291.
  • 19
    Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994; 12: 20222034.
  • 20
    Lynch TJ Jr., Herndon JE, Lyss AP, et al. Paclitaxel (P) + topotecan (T) + G-CSF for previously untreated extensive small cell lung cancer: preliminary analysis of Cancer and Leukemia Group B (CALGB) 9430 [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 491a.
  • 21
    Bunn PA, Kelly K, Crowley J, et al. Preliminary toxicity results from Southwest Oncology Group Trial 9705: a Phase II trial of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 468a.
  • 22
    Schiller JH, Adak S, Cella D, et al. Topotecan vs observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a Phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 21142122.
  • 23
    Hanna N, Lane KA, Ansari R, et al. Phase III trial of maintenance daily oral VP-16 versus no further therapy following induction chemotherapy with VP-16 plus ifosfamide plus cisplatin (VIP) in extensive stage small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) trial (LUN 93-2) [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 316a.
  • 24
    Gatzemeier V, von Pawel J, Macha H, et al. A Phase III trial of Taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate and vincristine (CEV) in previously untreated small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 483a.